Table 3.
Predictors of requiring tracking for retention support among patients retained in care at one year (N = 5318)
| Newly Linking to care (N = 1412) | Previously in Care (N = 3906) | |||||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Predictor | OR | 95% CI | Adj OR | 95% CI | OR | 95% CI | Adj OR | 95% CI |
| Region | ||||||||
| Kenya | ref | ref | ref | ref | ||||
| Uganda-East | 4.76 | 2.89 – 7.85 | 12.0 | 4.80 – 30.1 | 8.15 | 3.39 – 19.6 | 6.85 | 2.82 – 16.7 |
| Uganda-West | 1.51 | 0.84 – 2.71 | 1.25 | 0.50 – 3.15 | 2.0 | 1.51 – 2.66 | 0.75 | 0.30 – 1.85 |
| Sex | ||||||||
| Male | ref | ref | ref | ref | ||||
| Female | 0.85 | 0.66 – 1.08 | 0.68 | 0.52 – 0.89 | 0.98 | 0.76 – 1.27 | 0.70 | 0.52 – 0.95 |
| Age | ||||||||
| 15–24 years | 1.97 | 1.27 – 3.03 | 2.55 | 1.59 – 4.10 | 2.76 | 1.77 – 4.31 | 2.39 | 1.46 – 3.91 |
| 25–29 years | 1.84 | 1.24 – 2.75 | 2.00 | 1.30 – 3.07 | 2.05 | 1.38 – 3.07 | 1.90 | 1.21 – 2.99 |
| 30–34 years | 1.28 | 0.85 – 1.92 | 1.40 | 0.90 – 2.16 | 1.88 | 1.28 – 2.77 | 1.85 | 1.22 – 2.81 |
| 35–39 years | 1.35 | 0.90 – 2.05 | 1.44 | 0.93 – 2.24 | 1.28 | 0.87 – 1.89 | 1.25 | 0.81 – 1.92 |
| 40–44 years | 0.96 | 0.61 – 1.52 | 1.09 | 0.67 – 1.78 | 1.08 | 0.71 – 1.64 | 1.06 | 0.67 – 1.66 |
| > 45 years | ref | ref | ref | ref | ||||
| Education | ||||||||
| No School | 0.87 | 0.60 – 1.28 | 1.18 | 0.76 – 1.82 | 1.02 | 0.69 – 1.49 | 1.24 | 0.80 – 1.92 |
| Primary | ref | ref | ref | ref | ||||
| Any secondary or further | 0.92 | 0.65 – 1.32 | 0.97 | 0.65 – 1.42 | 0.84 | 0.58 – 1.22 | 0.99 | 0.66 – 1.47 |
| Occupation | ||||||||
| Formal | ref | ref | ||||||
| Informal – high risk | 1.22 | 0.54 – 2.75 | 1.64 | 0.75 – 3.58 | ||||
| Informal – low risk | 0.96 | 0.50 – 1.84 | 1.43 | 0.73 – 2.82 | ||||
| No job | 1.27 | 0.58 – 2.78 | 1.70 | 0.75 – 3.87 | ||||
| Other | 0.58 | 0.22 – 1.55 | 1.64 | 0.63 – 4.27 | ||||
| Own a mobile phone | ||||||||
| Yes | ref | ref | ref | ref | ||||
| No | 1.26 | 0.97 – 1.63 | 1.17 | 0.89 – 1.55 | 1.25 | 0.97 – 1.62 | 1.30 | 0.98 – 1.73 |
| Mobility | ||||||||
| Stable resident | ref | ref | ref | ref | ||||
| Not stable resident | 0.34 | 0.12 – 0.93 | 0.33 | 0.13 – 0.84 | 0.76 | 0.29 – 1.97 | 0.83 | 0.26 – 2.63 |
| Pre-ART CD4 | ||||||||
| Below country treatment guidelines | ref | ref | ref | ref | ||||
| Above country treatment guidelines | 3.19 | 2.43 – 4.19 | 3.16 | 2.39 – 4.18 | 10.1 | 7.49 – 13.6 | 9.52 | 7.00 – 12.9 |
| Site of testing | ||||||||
| CHC | ref | ref | ref | ref | ||||
| HBT | 0.85 | 0.63 – 1.15 | 0.87 | 0.62 – 1.20 | 1.13 | 0.82 – 1.55 | 1.08 | 0.77 – 1.53 |
| Time to link | ||||||||
| <= 30 days | ref | ref | ||||||
| > 30 days | 1.28 | 0.99 – 1.66 | 1.25 | 0.95 – 1.64 | ||||
Abbreviations: CI = Confidence Interval; CHC = Community Health Campaign; HBT = Home-based Testing
Country guidelines for treatment were to initiate ART at CD4 < 350 cells/ml until December 2013 in Uganda and until June 2014 in Kenya, after which country treatment guidelines were changed to reflect the 2013 WHO guidelines of ART initiation at CD4 < 500 cells/ml